Misek David E, Kim Evelyn H
Department of Surgery, University of Michigan Medical School, Ann Arbor, MI 48109-5656, USA.
Int J Proteomics. 2011;2011:343582. doi: 10.1155/2011/343582. Epub 2011 Aug 11.
Advances in breast cancer control will be greatly aided by early detection so as to diagnose and treat breast cancer in its preinvasive state prior to metastasis. For breast cancer, the second leading cause of cancer-related death among women in the United States, early detection does allow for increased treatment options, including surgical resection, with a corresponding better patient response. Unfortunately, however, many patients' tumors are diagnosed following metastasis, thus making it more difficult to successfully treat the malignancy. There are, at present, no existing validated plasma/serum biomarkers for breast cancer. Only a few biomarkers (such as HER-2/neu, estrogen receptor, and progesterone receptor) have utility for diagnosis and prognosis. Thus, there is a great need for new biomarkers for breast cancer. This paper will focus on the identification of new serum protein biomarkers with utility for the early detection of breast cancer.
早期检测将极大地推动乳腺癌防治工作的进展，以便在转移前的侵袭前状态诊断和治疗乳腺癌。在美国，乳腺癌是女性癌症相关死亡的第二大原因，早期检测确实能增加治疗选择，包括手术切除，患者的反应也相应更好。然而，不幸的是，许多患者的肿瘤在转移后才被诊断出来，因此成功治疗这种恶性肿瘤变得更加困难。目前，尚无经过验证的用于乳腺癌的血浆/血清生物标志物。只有少数生物标志物（如HER-2/neu、雌激素受体和孕激素受体）可用于诊断和预后。因此，迫切需要新的乳腺癌生物标志物。本文将重点关注可用于早期检测乳腺癌的新型血清蛋白生物标志物的鉴定。
